- Conditions
- Type 2 Diabetes, Cardiovascular Risk
- Interventions
- Zenagamtide, Insulin glargine U-100
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 1,778 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 109
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Montgomery, Alabama + 91 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Overweight, Obesity
- Interventions
- Zenagamtide, Semaglutide, Placebo (matched to semaglutide), Placebo (matched to zenagamtide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 43
- States / cities
- Lancaster, California • Palm Springs, California • Pomona, California + 38 more
- Conditions
- Overweight, Obesity
- Interventions
- zenagamtide, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 950 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 37
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Montgomery, Alabama + 32 more